The races to identify the specific populations that respond remarkably well or have dreadfully worst response to immune check point inhibitor (ICI) are hard-edged, especially because the cost of these drugs are so devastating that people are afraid that the widespread use will lead to the destruction of the insurance system and enhance the inequality of health among the patients according to individual economical status.